4-(溴甲基)-[1,1-联苯]-4-羧酸甲酯 | 306271-99-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(溴甲基)-[1,1-联苯]-4-羧酸甲酯
• 英文名称: methyl 4'-(bromomethyl)biphenyl-4-carboxylate
• 英文别名: Methyl 4'-(bromomethyl)-[1,1'-biphenyl]-4-carboxylate；methyl 4-[4-(bromomethyl)phenyl]benzoate
• CAS: 306271-99-8
• 化学式: C₁₅H₁₃BrO₂
• 分子量: 305.171
• InChiKey: ITBUSBAYFDTECF-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C
• 沸点：
  403.5±38.0 °C(Predicted)
• 密度：
  1.374±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trans-1,4-Diaminocyclohexane 、 4-(溴甲基)-[1,1-联苯]-4-羧酸甲酯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以97%的产率得到
  参考文献：
  名称：

  使用具有嵌入式环己基二胺核的柔性四羧酸酯连接基对配位聚合物进行晶体工程

  摘要：

  三个新的胺官能化四甲酸二接头与各种臂长度的合成，即Ñ，Ñ，Ñ ' Ñ ' -四（R1，R2或R3） -反式-1,4-二氨基环己烷，R1 =（4-羧基苯基） - 1-甲基; R2 =（4-肉桂基）-1-甲基; R3 ＝ 1′-羧基-[4，4′-联苯] -1-甲基。通过单晶结构分析并通过测量最远的氧原子获得的连接子的对角线长度，对于L1，L2和L3分别为19.4、24.6和27.5Å。SP 3环己基二胺核心的氨基与亚甲基间隔基的碳原子发生杂交，可使连接的基团围绕这些原子位点发生旋转，从而使配体具有以两个主要的主要构象形式表现出来的柔韧性：会聚，其中的羧基臂基团与同一氮原子连接的是π⋯π堆叠，并且发散，其中两个羧基臂占据赤道位置，两个羧基相对于配体的环己基核心占据轴向位置。从16种新的配位聚合物的晶体结构获得的总体配体构象分析表明，绝大多数（93％）最常见的构象是发散构象。获得的配位聚合物的分子式和拓扑结构为：聚[Cd

  DOI：

  10.1039/d0ce01620a
• 作为产物：
  描述：

  4-甲基-4-联苯基羧酸 在 甲醇 、 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 正己烷 、 苯 为溶剂， 生成 4-(溴甲基)-[1,1-联苯]-4-羧酸甲酯
  参考文献：
  名称：

  Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates

  摘要：

  The binding of the anti-HIV agent cosalane to CD4 is thought to involve ionic interactions of negatively charged carboxylates of the ligand with positively charged residues on the surface of the protein. An investigation of the optimal anion distances for anti-HIV activity in a series of cosalane tetracarboxylate analogues has been completed, and maximal activity results when the two proximal and the two distal carboxylates are separated by eight atoms. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00417-0

文献信息

• [EN] INHIBITORS OF CD40-CD154 BINDING<br/>[FR] INHIBITEURS DE LIAISON CD40-CD154
  申请人：TONIX PHARMACEUTICALS HOLDING CORP

  公开号：WO2020210831A1

  公开（公告）日：2020-10-15

  Disclosed herein are compounds including pharmaceutically acceptable salts, esters, prodrugs, hydrates and tautomers thereof which modulate the interactions of CD-40-CD40L. The compounds are useful for treating, ameliorating or preventing an autoimmune disease, inflammatory disease, or other immune-related disease in a patient in need of treatment.

  本文披露了包括药用可接受的盐、酯、前药、水合物和互变异构体在内的化合物，这些化合物调节CD-40-CD40L的相互作用。这些化合物可用于治疗、改善或预防患有自身免疫疾病、炎症性疾病或其他免疫相关疾病的患者。
• Quinazolines as MMP-13 inhibitors
  申请人：——

  公开号：US20020193377A1

  公开（公告）日：2002-12-19

  A compound selected from those of formula (I): 1 in which: R 1 represents a group selected from hydrogen, amino, alkyl, alkenyl, aminoalkyl, aryl, arylalkyl, heterocycle, and cycloalkylalkyl, optionally substituted, W represents oxygen, sulfhur, or ═N—R′, in which R′ is as defined in the description, X 1 , X 2 and X 3 represent nitrogen or —C—R 6 in which R 6 is as defined in the description, Y represents oxygen, sulfhur, —NH, or —N(C 1 -C 6 )alkyl, Z represents oxygen, sulfhur, —NR 7 in which R 7 is as defined in the description, and 59 optionally carbon atom, n is an integer from 1 to 8 inclusive, Z 1 represents —CR 8 R 9 wherein R 8 and R 9 are as defined in the description, A represents aromatic or non-aromatic, heterocyclic or non-heterocyclic ring system, m is an integer from 0 to 7 inclusive, the group(s) R 2 is (are) is as defined in the description, R 3 represents hydrogen, alkyl, alkenyl, alkynyl, ot a group of formula: 2 in which Z 2 , B, R 5 , P and q are as defined in the description, optionally, the racemic forms thereof, isomers thereof, N-oxydes thereof, and the pharmaceutically acceptable salts thereof, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.

  从以下化学式（I）中选择的一种化合物： 其中： R1代表从氢、氨基、烷基、烯基、氨基烷基、芳基、芳基烷基、杂环和环烷基烷基中选择的基团，可选择取代； W代表氧、硫或═N—R′，其中R′如描述中定义； X1、X2和X3代表氮或—C—R6，其中R6如描述中定义； Y代表氧、硫、—NH或—N（C1-C6）烷基； Z代表氧、硫、—NR7，其中R7如描述中定义，且可选地是碳原子； n为1到8之间的整数； Z1代表—CR8R9，其中R8和R9如描述中定义； A代表芳香或非芳香、杂环或非杂环环系统； m为0到7之间的整数； R2代表如描述中定义的基团； R3代表氢、烷基、烯基、炔基或化学式2中的基团： 其中Z2、B、R5、P和q如描述中定义； 可选地，它们的外消旋体、异构体、N-氧化物和药学上可接受的盐，以及含有它们的药物制剂，可用作特异性抑制剂13型基质金属蛋白酶。
• PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE
  申请人：Eisai Co., Ltd.

  公开号：EP0627433A1

  公开（公告）日：1994-12-07

  The invention provides an industrially excellent process for producing a 2-alkyl-3-(biphenyl-4-yl)-methyl-3H-imidazo[4,5-b]pyridine derivative represented by general formula (II), serving as a precursor of the angiotensin II receptor antagonist useful as an antihypertensive, a biphenyl derivative serving as a precursor of the substituent of the imidazopyridine derivative, a process for producing the biphenyl derivative, and an intermediate useful for producing the biphenyl derivative. The imidazopyridine derivative (II) can be produced in a high yield according to the process of the invention by subjecting a 2-amino-5-halogeno-3-nitropyridine derivative to amidation, N-alkylation and reductive cyclization. This process is industrially excellent, because the halogen atom introduced into the 5-position as a protective group in the nitration step can be eliminated simultaneously in the subsequent step. The above biphenyl derivative is excellent in reactivity and product purity, thus being an intermediate suitable for industrial production.

  本发明提供了一种生产通式(II)代表的 2-烷基-3-(联苯-4-基)-甲基-3H-咪唑并[4,5-b]吡啶衍生物的工业化优良工艺，该衍生物可作为血管紧张素 II 受体拮抗剂的前体，用于抗高血压、作为咪唑并吡啶衍生物取代基前体的联苯衍生物，生产联苯衍生物的工艺，以及生产联苯衍生物的中间体。根据本发明的工艺，通过对 2-氨基-5-卤代-3-硝基吡啶衍生物进行酰胺化、N-烷基化和还原环化，可以高产率生产出咪唑吡啶衍生物 (II)。由于在硝化步骤中作为保护基团引入 5 位的卤素原子可以在后续步骤中同时消除，因此该工艺在工业上非常出色。上述联苯衍生物在反应活性和产品纯度方面都非常出色，因此是一种适合工业化生产的中间体。
• Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors
  作者：Ana I. Sánchez、Valentín Martínez-Barrasa、Carolina Burgos、Juan J. Vaquero、Julio Alvarez-Builla、Emma Terricabras、Víctor Segarra

  DOI：10.1016/j.bmc.2013.01.067

  日期：2013.4

  The latest scientific findings concerning PDE7 and PDE4 inhibition suggest that selective small-molecule inhibitors of both enzymes could provide a novel approach to treat a variety of immunological diseases. In this context, we describe a new series of quinazoline derivatives from quinazolin-4-thiones which include a substituted biphenyl fragment. Some of these compounds show inhibitory potencies at sub-micromolar levels against the catalytic domain of PDE7. (C) 2013 Elsevier Ltd. All rights reserved.
• Correlation of Anti-HIV Activity with Anion Spacing in a Series of Cosalane Analogues with Extended Polycarboxylate Pharmacophores
  作者：Kalpathy C. Santhosh、Gitendra C. Paul、Erik De Clercq、Christophe Pannecouque、Myriam Witvrouw、Tracy L. Loftus、Jim A. Turpin、Robert W. Buckheit,、Mark Cushman

  DOI：10.1021/jm000290u

  日期：2001.3.1

  Cosalane and its synthetic derivatives inhibit the binding of gp120 to CD4 as well as the fusion of the viral envelope with the cell membrane. The binding of the cosalanes to CD4 is proposed to involve ionic interactions of the negatively charged carboxylates of the ligands with positively charged arginine and lysine amino acid side chains of the protein. To investigate the effect of anion spacing on anti-HIV activity in the cosalane system, a series of cosalane tetracarboxylates was synthesized in which the two proximal and two distal carboxylates are separated by 6-12 atoms. Maximum activity was observed when the proximal and distal carboxylates are separated by 8 atoms. In a series of cosalane amino acid derivatives containing glutamic acid, glycine, aspartic acid, beta -alanine, leucine, and phenylalanine residues, maximum activity was displayed by the di(glutamic acid) analogue. A hypothetical model has been devised for the binding of the cosalane di(glutamic acid) conjugate to CD4. In general, the compounds in this series are more potent against HIV-1(RF) in CEM-SS cells than they are vs HIV-1(IIIB) in MT-4 cells, and they are least potent vs HIV-2(ROD) in MT-4 cells.